Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07197502 · ClinicalTrials.gov registry record · NA

Treatment of Borderline Personality Disorder With rTMS

A NA study of Borderline Personality Disorder and Borderline Personality, sponsored by University of California, Los Angeles.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
2
Study locations

NCT07197502: Recruiting NA study of Borderline Personality Disorder and Borderline Personality, sponsored by University of California, Los Angeles.

NCT07197502 is a NA study of Borderline Personality Disorder and Borderline Personality that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 30 participants, below the 106-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07197502, a NA study of Borderline Personality Disorder and Borderline Personality, is actively recruiting participants, sponsored by University of California, Los Angeles.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

This project studies the effectiveness of brain stimulation on borderline personality disorder (BPD) symptoms. This study is blinded, randomized and will enroll up to 30 participants. Participant will be consented for the study remotely via a secure internet platform called Zoom. Participants will undergo up to 2 MRI scans, 2 brain wave recording sessions and up to 30 brain stimulation treatments, and complete symptom assessments and cognitive behavioral tasks on a computer. Participation requires minimum of 17 in person visits over the course of 2.5 months. Participants are randomly assigned active or sham brain stimulation. Participants who received sham brain stimulation have the option to receive additional 15 active brain stimulation session.

Primary Outcome

Borderline Symptom List 23 (BSL-23)

Conditions Studied

Borderline Personality Disorder Borderline Personality BPD - Borderline Personality Disorder

Interventions

  • DEVICE Transcranial Magnetic Stimulation (TMS)

Study Locations (2)

California

  • Semel Institute for Neuroscience and Human Behavior at UCLA - Los Angeles
  • Semel Institute/ UCLA TMS - Los Angeles

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-03-01
Est. Completion 2027-12-31
Phase NA
University of California, Los Angeles

897 total trials

What NCT07197502 shows while recruiting

NCT07197502 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 106-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target (72% lower).

The record links to 3 conditions, with Borderline Personality Disorder appearing as the primary indexed condition, and to 1 intervention - of which Transcranial Magnetic Stimulation (TMS) is the first listed.

NCT07197502 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT07197502 about?

NCT07197502 is a clinical study titled "Treatment of Borderline Personality Disorder With rTMS". This project studies the effectiveness of brain stimulation on borderline personality disorder (BPD) symptoms. This study is blinded, randomized and will enroll up to 30 participants. Participant will be consented for the study remotely via a secure internet platform called Zoom. Participants will...

What is the current status of trial NCT07197502?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-03-01. Estimated completion is 2027-12-31.

What conditions does trial NCT07197502 study?

This clinical trial studies the following conditions: Borderline Personality Disorder, Borderline Personality, BPD - Borderline Personality Disorder.

What interventions are being tested in trial NCT07197502?

The interventions under investigation include: Transcranial Magnetic Stimulation (TMS) (DEVICE).

Who is sponsoring clinical trial NCT07197502?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07197502 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Borderline Personality Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07197502's enrollment target sits among peer trials

30 12th of 16 higher than 4 of 16 other Borderline Personality Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Borderline Personality Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07197502

Source: ClinicalTrials.gov NCT07197502, the US trial registry maintained by the National Library of Medicine. NCT07197502 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.